Background: Nosocomial infections are among the most common complications in hospitals. A major part is\ncaused by multidrug-resistant organisms (MDRO). MRSA is still the most prominent and frequent MDRO. The early\ndetection of carriers of multidrug-resistant bacteria is an effective measure to reduce nosocomial infections caused by\nMDRO. For patients who are planning to go to the hospital, an outpatient screening for MDRO and pre-hospital\ndecolonization is recommended. However, the effectiveness of such pre-admission MDRO management in preparation\nfor a planned hospital stay has not yet been sufficiently scientifically examined from an economic perspective.\nMethods: A decision tree will be used to develop scenarios for MDRO screening and treatment in the context of the\noutpatient and inpatient sectors using MRSA-positive patients as an example. Subsequently, the expected costs for the\nrespective strategy are presented.\nResults: The decision tree analysis shows that the expected costs of outpatient MRSA management are 8.24 Euro and that\nof inpatient MRSA management are 672.51 Euros.\nConclusion: The forward displacement of the MRSA screening to the ambulatory sector and any subsequent\noutpatient decolonization for patients with a planned hospitalization is the most cost-effective strategy and should\nbecome a standard benefit. Excluding opportunity costs, the expected costs of inpatient MRSA management are 54.94 Euros.
Loading....